Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Universität Münster GluN2B compound cis-13c
- Development stage
- Unknown
- Lead developer
- Universität Münster
01
Overview
Universität Münster GluN2B compound cis-13c: sourced facts only. name: "However, the introduction of lipophilic substituents at the quinolone N-atom resulted in more than 10-fold increased GluN2B affinity of the benzyl and benzyloxymethyl derivatives cis-13c (Ko = 36 nM) and 13e (Ko = 27 nM)." [PMID:38889396]; target: "However, the introduction of lipophilic substituents at the quinolone N-atom resulted in more than 10-fold increased GluN2B affinity of the benzyl and benzyloxymethyl derivatives cis-13c (Ko = 36 nM) and 13e (Ko = 27 nM)." [PMID:38889396]; developer: "Institut für Pharmazeutische und Medizinische Chemie, Universität Münster, Münster, Germany." [PMID:38889396]
02
Targets
GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)
Beyond the preview
Go deeper on Universität Münster GluN2B compound cis-13c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Universität Münster GluN2B compound cis-13c.